Origin Technologies, an affiliate of US-China genomics company Centrillion, raised its bid to acquire microarray-maker Affymetrix to $17 per share or $1.5 billion; Sequoia Capital China is raising up to $1.5 billion in two investment funds; Ally Bridge Group of China participated in a $155 million private placement for Tesaro, a Boston area oncology biotech; Shanghai Pharma raised $21 million for its online pharma; Shenzhen Hepalink Pharma and Canada’s Quest PharmaTech formed a $9 million JV to develop Quest’s cancer immunotherapies in China; Lilly Asia Ventures made an investment of undisclosed size in Millin, a Beijing dialysis device maker; CANbridge Life Sciences of Beijing in-licensed global rights to an AVEO Oncology cancer drug; Shanghai’s Zai Lab signed up Boehringer Ingelheim to provide CMO services at its Shanghai facility for a new Zai mAb; China is investigating the black-market distribution of $88 million worth of vaccines; and Zhejiang Medicine together with Ambrx of San Diego have started a Phase I trial of an antibody targeting HER2 cancer.
